BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
3.110
-0.280 (-8.26%)
At close: Sep 12, 2025, 4:00 PM EDT
3.170
+0.060 (1.93%)
After-hours: Sep 12, 2025, 7:58 PM EDT
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -64.59% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover BioXcel Therapeutics stock have a consensus rating of "Buy" and an average price target of $32.8, which forecasts a 954.66% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $80.
Price Target: $32.8 (+954.66%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 0 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +28.62% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +221.54% | Aug 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +221.54% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +221.54% | Aug 15, 2025 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +2,022.19% | Jul 15, 2025 |
Financial Forecast
Revenue This Year
811.51K
from 2.27M
Decreased by -64.19%
Revenue Next Year
5.66M
from 811.51K
Increased by 597.46%
EPS This Year
-5.41
from -23.51
EPS Next Year
-3.43
from -5.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1M | 11.3M | |||
| Avg | 811,512 | 5.7M | |||
| Low | 625,240 | 686,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -50.4% | 1,297.4% | |||
| Avg | -64.2% | 597.5% | |||
| Low | -72.4% | -15.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.85 | -1.03 | |||
| Avg | -5.41 | -3.43 | |||
| Low | -8.01 | -7.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.